JP2017514853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514853A5 JP2017514853A5 JP2016566286A JP2016566286A JP2017514853A5 JP 2017514853 A5 JP2017514853 A5 JP 2017514853A5 JP 2016566286 A JP2016566286 A JP 2016566286A JP 2016566286 A JP2016566286 A JP 2016566286A JP 2017514853 A5 JP2017514853 A5 JP 2017514853A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- agent
- composition according
- cancer
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 24
- 229960004622 raloxifene Drugs 0.000 claims description 20
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000003886 aromatase inhibitor Substances 0.000 claims description 18
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 229960001603 tamoxifen Drugs 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 229960002932 anastrozole Drugs 0.000 claims description 7
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 102000015694 estrogen receptors Human genes 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 4
- 229960000817 bazedoxifene Drugs 0.000 description 4
- -1 borozole Chemical compound 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960002367 lasofoxifene Drugs 0.000 description 4
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 4
- NOECSYBNZHIVHW-LKADTRSGSA-N [(2r,3as,3bs,5as,6r,8as,8br,10as)-2,6-diethynyl-3a,5a-dimethyl-2-propanoyloxy-1,3,3b,4,5,7,8,8a,8b,9,10,10a-dodecahydroindeno[5,4-e]inden-6-yl] propanoate Chemical compound C([C@]1(C)[C@](OC(=O)CC)(C#C)CC[C@H]1[C@@H]1CC2)C[C@@H]1[C@]1(C)[C@@H]2C[C@@](C#C)(OC(=O)CC)C1 NOECSYBNZHIVHW-LKADTRSGSA-N 0.000 description 3
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 3
- 229950005529 arzoxifene Drugs 0.000 description 3
- XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 description 3
- 229950002728 levormeloxifene Drugs 0.000 description 3
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 229950011548 fadrozole Drugs 0.000 description 2
- 229960004421 formestane Drugs 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229960003969 ospemifene Drugs 0.000 description 2
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410192569.2A CN104208069A (zh) | 2014-05-08 | 2014-05-08 | 双炔失碳酯组合物和疾病治疗方法 |
| CN201410192569.2 | 2014-05-08 | ||
| PCT/CN2015/077942 WO2015169173A1 (en) | 2014-05-08 | 2015-04-30 | Anordrin compositions and methods for treating diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019089931A Division JP2019142969A (ja) | 2014-05-08 | 2019-05-10 | アノルドリン組成物および疾患を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514853A JP2017514853A (ja) | 2017-06-08 |
| JP2017514853A5 true JP2017514853A5 (https=) | 2018-06-14 |
| JP6594339B2 JP6594339B2 (ja) | 2019-10-23 |
Family
ID=52090245
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566286A Active JP6594339B2 (ja) | 2014-05-08 | 2015-04-30 | アノルドリン組成物および疾患を処置するための方法 |
| JP2019089931A Withdrawn JP2019142969A (ja) | 2014-05-08 | 2019-05-10 | アノルドリン組成物および疾患を処置するための方法 |
| JP2020219768A Active JP7084467B2 (ja) | 2014-05-08 | 2020-12-29 | アノルドリン組成物および疾患を処置するための方法 |
| JP2022042432A Withdrawn JP2022078330A (ja) | 2014-05-08 | 2022-03-17 | アノルドリン組成物および疾患を処置するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019089931A Withdrawn JP2019142969A (ja) | 2014-05-08 | 2019-05-10 | アノルドリン組成物および疾患を処置するための方法 |
| JP2020219768A Active JP7084467B2 (ja) | 2014-05-08 | 2020-12-29 | アノルドリン組成物および疾患を処置するための方法 |
| JP2022042432A Withdrawn JP2022078330A (ja) | 2014-05-08 | 2022-03-17 | アノルドリン組成物および疾患を処置するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10231978B2 (https=) |
| EP (1) | EP3139928B1 (https=) |
| JP (4) | JP6594339B2 (https=) |
| CN (3) | CN113101292B (https=) |
| WO (1) | WO2015169173A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113101292B (zh) | 2014-05-08 | 2023-07-11 | 上海市生物医药技术研究院 | 双炔失碳酯组合物和疾病治疗方法 |
| CN105279394B (zh) * | 2015-10-13 | 2017-12-26 | 山西农业大学 | 用于神经肽受体筛选的方法 |
| JP6788255B2 (ja) * | 2015-11-19 | 2020-11-25 | 国立大学法人信州大学 | 新規ベクター及びこれを用いた可溶化タンパク質の製造方法 |
| US20180098963A1 (en) | 2016-10-11 | 2018-04-12 | Duke University | Lasofoxifene treatment of breast cancer |
| WO2018090049A1 (en) * | 2016-11-14 | 2018-05-17 | The Brigham And Women's Hospital, Inc. | Estrogen sensing through gper1 regulates normal and malignant liver growth |
| WO2018129645A1 (en) | 2017-01-10 | 2018-07-19 | Wang, Wei | Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment |
| WO2019041078A1 (en) * | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
| CN109662968B (zh) * | 2017-10-13 | 2021-05-18 | 上海奥奇医药科技有限公司 | 含A-失碳-5α雄甾烷化合物的升白制剂及其应用 |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| CN111773388B (zh) * | 2019-04-04 | 2023-07-18 | 上海奥奇医药科技有限公司 | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 |
| US20210299098A1 (en) * | 2020-03-31 | 2021-09-30 | Cipla Limited | Selective estrogen receptor modulator for treatment of pancreatic cancer |
| WO2022246634A1 (en) * | 2021-05-25 | 2022-12-01 | Zhejiang Jiachi Development Pharmaceuticals Ltd. | Compositions for treating insomnia and uses thereof |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001120A (en) * | 1989-05-10 | 1991-03-19 | Natural Pharmacia International, Inc. | Use of A-Nor-steroids as malignant cells growth inhibitors |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| BR0314126A (pt) * | 2002-09-20 | 2005-06-28 | Pfizer Prod Inc | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio |
| US20050227929A1 (en) * | 2003-11-13 | 2005-10-13 | Masferrer Jaime L | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent |
| US20070203102A1 (en) * | 2004-06-30 | 2007-08-30 | Blizzard Timothy A | Estrogen Receptor Modulators |
| JP5449775B2 (ja) | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
| CN101297970A (zh) * | 2006-03-17 | 2008-11-05 | 山东蓝金生物工程有限公司 | 同载抗代谢药物及其增效剂的抗癌缓释注射剂 |
| WO2007129062A1 (en) | 2006-05-08 | 2007-11-15 | Astex Therapeutics Limited | Pharmaceutical combinations of diazole derivatives for cancer treatment |
| CN101987081B (zh) * | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| US9220771B2 (en) | 2010-07-16 | 2015-12-29 | Merck Patent Gmbh | Peptide for use in the treatment of breast cancer and/or bone metastases |
| US20140134170A1 (en) | 2011-03-11 | 2014-05-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| CN102218069B (zh) * | 2011-04-08 | 2012-09-26 | 上海奥奇医药科技有限公司 | A-失碳-5α-雄甾烷化合物在制备抗恶性肿瘤药物中的应用 |
| CN113101292B (zh) | 2014-05-08 | 2023-07-11 | 上海市生物医药技术研究院 | 双炔失碳酯组合物和疾病治疗方法 |
-
2014
- 2014-05-08 CN CN202110246492.2A patent/CN113101292B/zh active Active
- 2014-05-08 CN CN201410192569.2A patent/CN104208069A/zh active Pending
- 2014-05-08 CN CN202010899146.XA patent/CN111956653B/zh active Active
-
2015
- 2015-04-30 US US15/309,426 patent/US10231978B2/en active Active
- 2015-04-30 JP JP2016566286A patent/JP6594339B2/ja active Active
- 2015-04-30 EP EP15788674.8A patent/EP3139928B1/en active Active
- 2015-04-30 WO PCT/CN2015/077942 patent/WO2015169173A1/en not_active Ceased
-
2019
- 2019-01-30 US US16/262,617 patent/US10857158B2/en active Active
- 2019-05-10 JP JP2019089931A patent/JP2019142969A/ja not_active Withdrawn
-
2020
- 2020-11-19 US US16/953,168 patent/US11911397B2/en active Active
- 2020-12-29 JP JP2020219768A patent/JP7084467B2/ja active Active
-
2022
- 2022-03-17 JP JP2022042432A patent/JP2022078330A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514853A5 (https=) | ||
| Peng et al. | Altered glycolysis results in drug-resistant in clinical tumor therapy | |
| US10166246B2 (en) | TGR5 agonist complexes for treating diabetes and cancer | |
| Mehta et al. | Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association | |
| AU2012341028C1 (en) | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof | |
| Wei et al. | Development of GLUT4-selective antagonists for multiple myeloma therapy | |
| Laderian et al. | CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib | |
| Stan et al. | Breast cancer survivorship issues | |
| Ongaro et al. | Sarcopenia in gastric cancer: when the loss costs too much | |
| JP2019142890A (ja) | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 | |
| JP6870046B2 (ja) | 癌治療 | |
| CN111285913B (zh) | 用于肿瘤治疗的11-脱氧皮质醇的17α,21-二酯 | |
| CN101990434B (zh) | 用于治疗沙粒病毒感染的抗病毒药物 | |
| RU2717331C2 (ru) | Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени | |
| Esteva et al. | Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer | |
| Jiang et al. | Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs | |
| US20160250211A1 (en) | Aurora kinase inhibitors | |
| Yardley | Adverse Event Management of mTOR Inhibitors during treatment of hormone receptor–positive advanced breast cancer: considerations for oncologists | |
| CN105283456B (zh) | 5-溴-靛玉红 | |
| AU2010236181B2 (en) | Method of treating hepatocellular carcinoma | |
| Rabiee et al. | Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis | |
| Zhang et al. | Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer | |
| Hong et al. | A novel Glycyrrhiza glabra extract liquiritin targeting NFATc1 activity and ROS levels to counteract ovariectomy-induced osteoporosis and bone loss in murine model | |
| JP2016525530A5 (https=) | ||
| WO2022232142A1 (en) | G-alpha-s inhibitors and uses thereof |